PredicTOR: predicting patient response to mTOR pathway inhibitors prior to treatm

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$649,622.00
Award Year:
2008
Program:
SBIR
Phase:
Phase II
Contract:
2R44CA123994-02
Award Id:
85395
Agency Tracking Number:
CA123994
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
20/20 GENESYSTEMS, INC., 9700 GREAT SENECA HWY, ROCKVILLE, MD, -
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
136134686
Principal Investigator:
WILLIAM JAMES
(301) 435-7882
BJAMES@2020GENE.COM
Business Contact:
() -
gtroy@202gene.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): We propose to develop a novel method and kit for profiling the expression and activation of signal transduction proteins in breast tumors. The goal is to create new companion diagnostics to better select patients like ly to respond to targeted therapies, including Herceptin. and novel tyrosine kinase inhibitors. 20/20 will utilize its proprietary Layered Expression Scanning (LES) technology. Transfer of antibody probes from a single tissue section to numerous bioaffinit y membranes permits multiple target antigens (up to 50 if needed) to be assessed in a quantitative manner while preserving the local spatial orientation of the targets relative to the tissue section. During Phase II, we will demonstrate its tissue applicat ions with human breast tissue sections from clinical trials in breast cancer patients treated with growth factor and Akt inhibitors. Biomarker quantification will be standardized and calibrated to clearly demonstrate a clinical benefit in comparison with s ubjective visual estimation. The product would have utility in both a research and clinical laboratory setting. Importantly, the system is open-ended to the addition of new prognostic markers and drug targets into the assay panel. There are several anticip ated advantages of the layered membrane platform over current histopathology tools such as immunohistochemistry (IHC). These include conservation of tissue (such as for core needle biopsies) and the ability to simultaneously profile multiple signaling prot eins in both normal and phosphorylated form, in a single tissue section. PUBLIC HEALTH RELEVANCE:Our options for breast cancer diagnosis and treatment will be increasingly taking advantage of information obtained from tumor profiling assays, which will ind icate customized therapies for each form of the disease. The novel diagnostic techniques to be researched will allow for microscopic profiling of tiny amounts of tissue for numerous cancer-causing molecules. There will be applications in pre-clinical studi es and drug trials, which will aim to invent novel treatment strategies using combinations of drugs that block growth factor' molecules.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government